CSIMarket Company Name, Ticker, Industry, else..
 
Cardiff Oncology Inc   (NASDAQ: CRDF)
 
Price: $1.0900 $0.01 0.926%
Day's High: $1.100000023841858 Week Perf: 10.1 %
Day's Low: $ 1.07 30 Day Perf: 13.54 %
Volume (M): 437,284 52 Wk High: $ 3.31
Volume (M$): $ 0 52 Wk Avg: $1.81
Open: $1.08 52 Wk Low: $0.76



 Market Capitalization (Millions $) 75
 Shares Outstanding (Millions) 68
 Employees 31
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -40
 Cash Flow (TTM) (Millions $) -2
 Capital Exp. (TTM) (Millions $) 0

Business Description


Cardiff Oncology Inc. is a biopharmaceutical company focused on the development of innovative cancer treatments. The company is based in San Diego, California, and is dedicated to improving outcomes for cancer patients. Cardiff Oncology's primary focus is on developing therapies that target solid tumors with significant unmet medical needs. The company utilizes its proprietary drug candidates and utilizes cutting-edge technology to identify potential solutions for cancer treatment. Their goal is to develop effective therapies that have minimal side effects and provide better treatment options for patients suffering from various types of cancer.


   Company Address: 11055 Flintkote Avenue San Diego 92121 CA
   Company Phone Number: 952-7570   Stock Exchange / Ticker: NASDAQ CRDF


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CCCC   -2.34%    
CRIS   -9.4%    
CVM        4.49% 
INBX   -1.82%    
INTS   -3.53%    
TIL      0% 
• View Complete Report
   



Clinical Study

Hope on the Horizon Positive Phase 1b Data for Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negati...

Published Mon, Jun 2 2025 8:47 PM UTC

At the recent American Society of Clinical Oncology (ASCO) 2025 meeting, Cardiff Oncology presented promising results from an investigator-initiated Phase 1b clinical trial evaluating the combination of onvansertib and paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). This aggressive form of breast cancer, known for its resistance to standard ther...
Clinical Study

Cardiff Oncologys Breakthrough in RAS-mutated mCRC Trial Amidst Revenue Setbacks

Published Tue, Dec 10 2024 11:00 AM UTC

The landscape of drug development for metastatic colorectal cancer (mCRC) is ever-evolving, with a focus on targeted therapies that can improve patient outcomes. Cardiff Oncology Inc. recently announced positive initial data from their Phase 2 CRDF-004 clinical trial, which is evaluating the combination of onvansertib with standard care for first-line treatment in RAS-mutate...
Clinical Study

Advancements in Treatment: Cardiff Oncology Reports Positive Results and New Lead Program for RAS-Mutated mCRC

Published Thu, Feb 29 2024 9:07 PM UTC

In a recent announcement, Cardiff Oncology unveiled the results for the fourth quarter and full year of 2023, along with an exciting business update. The company reported substantial progress towards their new lead program in the treatment of RAS-mutated metastatic colorectal cancer (mCRC), made possible through collaboration with the FDA and clinical execution from Pfizer I...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 12.11
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 146.76
Price to Sales (Expected) -
Price to Book 2.81
PEG (TTM) 0.15

Financial Strength Current
Quick Ratio 7.04
Working Capital Ratio 7.14
Leverage Ratio (MRQ) 0.41
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 0.09 $
Revenues (TTM) 0.01 $
Cash Flow (TTM) -
Cash 1.11 $
Book Value 0.39 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 16,387
Net Income per Employee (TTM) -1,291,968
Receivable Turnover Ratio (TTM) 2.49
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.01

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) -9245.19 %
Net Margin (MRQ) -8876.92 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Cardiff Oncology Inc's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.